4.8 News Item

FDA approves Genentech′s bispecific antibody for lymphoma

Journal

NATURE MEDICINE
Volume 29, Issue 3, Pages 507-508

Publisher

NATURE PORTFOLIO
DOI: 10.1038/d41591-023-00010-0

Keywords

-

Ask authors/readers for more resources

Nature Medicine investigates the latest advancements in translational and clinical research, featuring ongoing clinical trial data of mosunetuzumab in patients with relapsed or refractory follicular lymphoma.
Nature Medicine explores the latest translational and clinical research news, with data from an ongoing clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available